# Daratumumab in Combination With ATRA

> **NCT02751255** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 60 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** all-trans retinoic acid (ATRA)

## Key facts

- **NCT ID:** NCT02751255
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-06
- **Primary completion:** 2022-10-18
- **Final completion:** 2022-10-18
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-04-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02751255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02751255, "Daratumumab in Combination With ATRA". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02751255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*